research Therapeutic potential of oral tofacitinib in alopecia areata: a retrospective study
Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
Search
for
Sort by
Research
660-690 / 1000+ results 
research 53028 Semaglutide and Hair Loss: A Real-World Analysis
Semaglutide does not significantly increase the risk of hair loss.
research Onset of lichen planopilaris during treatment with etanercept
Etanercept may cause lichen planopilaris, so doctors should be cautious.
research Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
research Redox-Modulatory and MET-Inhibitory Triad: Synergistic Cytotoxicity of L-cysteine, NAC, and MET Inhibition in Cervical Cancer Cells
Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.
research Anti-inflammatory and anti-hyperplastic effect of Bazhengsan in a male rat model of chronic nonbacterial prostatitis
Bazhengsan reduces inflammation and tissue growth in chronic prostatitis.
research Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
research P075 A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib was more effective than methotrexate for treating alopecia areata.
research Blinding in Placebo-Controlled Trials
The conclusion suggests that the zinc lozenge study is valid despite imperfect blinding, as many participants could not correctly identify their lozenge type.
research Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
Tofacitinib helped a woman with total-body hair loss grow her hair back.
research BIOBRAN MGN-3
Biobran MGN-3 reduces chemotherapy side effects and improves quality of life for breast cancer patients.
research Local infusion of infliximab for the treatment of acute joint inflammation
Co-trimoxazole may help treat autoimmune diseases.
research Development of Alopecia Areata Universalis in a Patient Receiving Adalimumab
Adalimumab may cause severe hair loss in some patients.
research Curcumin-zinc framework encapsulated microneedle patch for promoting hair growth
A patch with curcumin-zinc can improve hair growth and health by delivering beneficial particles to the skin, increasing hair follicles, and reversing effects of a hair loss hormone.
research LOSING SIGHT OF THE DIAGNOSIS: A CASE REPORT OF NEUROMYELITIS OPTICA SPECTRUM DISEASE AND SYSTEMIC LUPUS ERYTHEMATOSUS-NEUROAUTOIMMUNITY IN FOCUS, CORRELATION OR COINCIDENCE?
Correct diagnosis is crucial for treating overlapping conditions like NMOSD and SLE effectively.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
research Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B
research Mechanism of action of NLRP3 protein macromolecule based on electrochemical sensors in the treatment of alopecia areata in mice: The role of Ritlecitinib in AA mice through NLRP3
research 438 Laminin-511 is a new player in the development of psoriasis and controlled via cannabinoid receptor type 1
Laminin-511 is involved in psoriasis development and can be regulated by cannabinoid receptor type 1.
research Lack of classic histology should not prevent diagnosis of necrolytic acral erythema
Consider necrolytic acral erythema in similar cases and treat with oral zinc sulfate.
research Treatment of Alopecia Areata with Simvastatin/Ezetimibe
Simvastatin/ezetimibe may help treat new cases of alopecia areata but not long-term cases.
research Editor’s picks January 2021
PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.
research Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
research Combined C3b and Factor B Autoantibodies and MPGN Type II
The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.
research Drug-Induced Alopecia Areata From Upadacitinib
Upadacitinib may cause hair loss.
research UTMD Enhances Targeting of Diclofenac and Doxil® to Boost Tumor Immunotherapy
research Identification of xenobiotics interfering with 5 α -reductase (SRD5A2) activity
MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
research Protolytic Equilibria of Cetirizine in the Presence of Micelle-Forming Surfactants
Micelles can change cetirizine's ionization, affecting its effectiveness in treatments.
research Ruxolitinib: A novel molecule in the management of dermatological disorders
Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.
research Editor's Picks August 2023
Anti-IL17A therapy reduced venous leg ulcer size by 64% without major side effects.